Scientists test new HIV vaccine strategy in early human trial
NCT ID NCT05471076
Summary
This early-stage study is testing two experimental HIV vaccine regimens in 52 healthy adults without HIV. The main goals are to check if the vaccines are safe and to see if they can trigger the immune system to produce special antibodies that might protect against many strains of HIV. Researchers are comparing different dosing methods to see which works best at training the body's defenses.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Alabama CRS
Birmingham, Alabama, 35222, United States
-
Bridge HIV CRS
San Francisco, California, 94102, United States
-
Brigham and Women's Hospital Vaccine CRS (BWH VCRS)
Boston, Massachusetts, 02115-6110, United States
-
Columbia P&S CRS
New York, New York, 10032, United States
-
Seattle Vaccine and Prevention CRS
Seattle, Washington, 98104, United States
-
The Ponce de Leon Center CRS
Atlanta, Georgia, 30308-2012, United States
Conditions
Explore the condition pages connected to this study.